Home › MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA (pembrolizumab) for Advanced Gastric Cancer
 

Keywords :   


MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA (pembrolizumab) for Advanced Gastric Cancer

2015-10-22 13:30:46| Merck.com - Product News

Dateline City: ROCKVILLE, Md. and KENILWORTH, N.J. Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer ROCKVILLE, Md.and KENILWORTH, N.J. Language: English read more

Tags: advanced study combination cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.04New law aims to protect devices from hackers
28.04National Coalition to End Period Poverty Launched
28.04PZ Cussons To Sell St. Tropez & Aveda Launches Curl Care Line
28.04Beauty Enthusiasts Eye Burgundy Mascara
28.04Distinctive Assets Distributes Mother\'s Day in Hollywood Celebrity Gift Boxes
28.04Musk in China to discuss full self driving - reports
28.04Weekly Recap: U.K. Government Announces Plastic Wipes Ban; Unicharm Starts Selling Recycled Diaper
28.04'Buying a first home is harder when you're single'
More »